Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

176.40 -0.41 (-0.23%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,221,141
Open 175.01
Bid (Size) 176.50 (3)
Ask (Size) 177.00 (1)
Prev. Close 176.81
Today's Range 173.41 - 179.14
52wk Range 115.03 - 376.65
Shares Outstanding 387,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Is Novavax Stock a Buy Now?
There's probably not much good news coming for this biotech in the near future. 
Via The Motley Fool
The Worst Mistake Moderna Investors Can Make in 2023
Moderna faces a major transition in 2023. 
Via The Motley Fool

Performance

YTD
-24.95%
-24.95%
1 Month
+22.41%
+22.41%
3 Month
+28.52%
+28.52%
6 Month
+21.38%
+21.38%
1 Year
-46.49%
-46.49%

More News

Read More
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Via Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Via Benzinga
Novavax Stock: Buy, Sell, or Hold in 2023?
Via The Motley Fool
Why Moderna Stock Popped Today
Via The Motley Fool
7 Stocks on the Perfect 10 List
Via InvestorPlace
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cathie Wood Increases Stake In 4 Stocks By Over 1,000% - Plus 4 New Holdings For Ark
Via Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
The 25 Best Stocks to Buy for Retirement
Via InvestorPlace
These Wildly Undervalued Stocks Could Go Parabolic
Via The Motley Fool
Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review
Via Investor's Business Daily
Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
Via Investor's Business Daily
2 Concerning Trends That Make Moderna a Risky Buy
Via The Motley Fool
David Jiménez Joins Moderna As U.S. General Manager
Via ACCESSWIRE
3 Stocks I'm Planning to Buy Very Soon
Via The Motley Fool
Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year
Via ACCESSWIRE
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
Via FinancialNewsMedia
Exposures COVID-19
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
Via Benzinga
Cognex, Nucor, Moderna And This Cybersecurity Company Feature On CNBC's 'Final Trades'
Via Benzinga
Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride
Via Investor's Business Daily
Moderna Stock Is Surging Today: What's Going On?
Via Benzinga
Moderna Says Omicron Tailored COVID-19 Shots Shows Better Immune Response Than Original Vaccine
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.